The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures
- PMID: 32332015
- PMCID: PMC8772618
- DOI: 10.1158/1078-0432.CCR-19-3416
The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures
Abstract
Purpose: Clinical trials with immune checkpoint inhibition in sarcomas have demonstrated minimal response. Here, we interrogated the tumor microenvironment (TME) of two contrasting soft-tissue sarcomas (STS), rhabdomyosarcomas and undifferentiated pleomorphic sarcomas (UPS), with differing genetic underpinnings and responses to immune checkpoint inhibition to understand the mechanisms that lead to response.
Experimental design: Utilizing fresh and formalin-fixed, paraffin-embedded tissue from patients diagnosed with UPS and rhabdomyosarcomas, we dissected the TME by using IHC, flow cytometry, and comparative transcriptomic studies.
Results: Our results demonstrated both STS subtypes to be dominated by tumor-associated macrophages and infiltrated with immune cells that localized near the tumor vasculature. Both subtypes had similar T-cell densities, however, their in situ distribution diverged. UPS specimens demonstrated diffuse intratumoral infiltration of T cells, while rhabdomyosarcomas samples revealed intratumoral T cells that clustered with B cells near perivascular beds, forming tertiary lymphoid structures (TLS). T cells in UPS specimens were comprised of abundant CD8+ T cells exhibiting high PD-1 expression, which might represent the tumor reactive repertoire. In rhabdomyosarcomas, T cells were limited to TLS, but expressed immune checkpoints and immunomodulatory molecules which, if appropriately targeted, could help unleash T cells into the rest of the tumor tissue.
Conclusions: Our work in STS revealed an immunosuppressive TME dominated by myeloid cells, which may be overcome with activation of T cells that traffic into the tumor. In rhabdomyosarcomas, targeting T cells found within TLS may be key to achieve antitumor response.
©2020 American Association for Cancer Research.
Conflict of interest statement
Disclosure of Potential Conflicts of Interest
G. Cojocaru is an employee/paid consultant for Compugen LTD. C.F. Meyer is an employee/paid consultant for Bayer, and reports receiving speakers bureau honoraria from Novartis. D.J. McConkey is an employee/paid consultant for Janssen, Rainier, and H3 Biomedicine, and reports receiving commercial research grants from Astra-Zeneca and Rainier. No potential conflicts of interest were disclosed by the other authors.
Figures







Similar articles
-
Impact of Tertiary Lymphoid Structure on Prognosis and Tumor Microenvironment in Undifferentiated Pleomorphic Sarcoma.Cancer Sci. 2025 May;116(5):1464-1473. doi: 10.1111/cas.70018. Epub 2025 Feb 25. Cancer Sci. 2025. PMID: 40007136 Free PMC article.
-
TLS and immune cell profiling: immunomodulatory effects of immunochemotherapy on tumor microenvironment in resectable stage III NSCLC.Front Immunol. 2024 Dec 11;15:1499731. doi: 10.3389/fimmu.2024.1499731. eCollection 2024. Front Immunol. 2024. PMID: 39726591 Free PMC article.
-
Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13+CD103+CD8+ Tissue-Resident Memory T-Cell Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy.Gastroenterology. 2024 Jun;166(6):1069-1084. doi: 10.1053/j.gastro.2023.10.022. Epub 2023 Oct 29. Gastroenterology. 2024. PMID: 38445519
-
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.Front Immunol. 2021 Dec 3;12:775761. doi: 10.3389/fimmu.2021.775761. eCollection 2021. Front Immunol. 2021. PMID: 34925348 Free PMC article. Review.
-
Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression.Front Immunol. 2025 May 29;16:1595070. doi: 10.3389/fimmu.2025.1595070. eCollection 2025. Front Immunol. 2025. PMID: 40510364 Free PMC article. Review.
Cited by
-
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.Signal Transduct Target Ther. 2024 Aug 28;9(1):225. doi: 10.1038/s41392-024-01947-5. Signal Transduct Target Ther. 2024. PMID: 39198425 Free PMC article. Review.
-
Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy.Nat Commun. 2020 Dec 17;11(1):6410. doi: 10.1038/s41467-020-19917-0. Nat Commun. 2020. PMID: 33335088 Free PMC article.
-
Activation-induced cytidine deaminase in tertiary lymphoid structures: dual roles and implications in cancer prognosis.Front Oncol. 2025 Apr 9;15:1555491. doi: 10.3389/fonc.2025.1555491. eCollection 2025. Front Oncol. 2025. PMID: 40270606 Free PMC article. Review.
-
Tertiary lymphoid structures and their therapeutic implications in cancer.Cell Oncol (Dordr). 2024 Oct;47(5):1579-1592. doi: 10.1007/s13402-024-00975-1. Epub 2024 Aug 12. Cell Oncol (Dordr). 2024. PMID: 39133439 Review.
-
Cancer-Associated B Cells in Sarcoma.Cancers (Basel). 2023 Jan 19;15(3):622. doi: 10.3390/cancers15030622. Cancers (Basel). 2023. PMID: 36765578 Free PMC article. Review.
References
-
- Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995, NCI. Available from: https://seer.cancer.gov/archive/publications/childhood/childhood-monogra....
-
- Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Res 2013;33:2597–604. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials